C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 8.88 HKD -6.23% Market Closed
Market Cap: 2.8B HKD

Wall Street
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 11.05 HKD with a low forecast of 8.08 HKD and a high forecast of 15.96 HKD.

Lowest
Price Target
8.08 HKD
9% Downside
Average
Price Target
11.05 HKD
24% Upside
Highest
Price Target
15.96 HKD
80% Upside
Cutia Therapeutics Competitors:
Price Targets
DVAX
Dynavax Technologies Corp
137% Upside
LYEL
Lyell Immunopharma Inc
68% Upside
ZBIO
Zenas Biopharma Inc
228% Upside
ELUT
Elutia Inc
266% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
4% Upside
GLPG
Galapagos NV
23% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
31% Upside
PRAX
Praxis Precision Medicines Inc
111% Upside

Revenue
Forecast

Revenue Estimate
Cutia Therapeutics

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 70%.

396%
Past Growth
70%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Cutia Therapeutics's stock price target?
Price Target
11.05 HKD

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 11.05 HKD with a low forecast of 8.08 HKD and a high forecast of 15.96 HKD.

What is Cutia Therapeutics's Revenue forecast?
Projected CAGR
70%

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 70%.

Back to Top